Developer docs
API playgroundTry for free, no card

Search company profiles

ActoBio Therapeutics

Full company profile

uuid000vgt3

Namestring
ActoBio Therapeutics
Legal namestring
ActoBio Therapeutics, Inc.
Websiteurl
https://actobio.com/
Company typeenum
Private
Founded yearint
2006
Descriptiontext

ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs. It develops a new class of therapeutic agents called ActoBiotics, a targeted, microbe-based, specifically designed agents that locally provide potential disease-modifying therapeutics to treat a range of disorders, such as immune-related diseases. ActoBiotics is based on the safe food-grade bacterium, Lactococcus lactis, which is used in the making of cheeses and other foods. Lactococcus lactis is engineered to develop specific therapeutic agents for delivery directly to the relevant tissue, thus making therapeutic applications across many diseases. This holds safer and more efficacious treatments than injectable agents. The company has a strong research and development pipeline with stage candidate in Phase IIb, and an extensive portfolio of candidates ready for clinical development across a wide range of potential indications. ActoBio Therapeutics was founded on 2006 and is headquartered in Ghent. Belgium.

Short descriptiontext

ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGhent, Belgium
HQ citystring
Ghent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic agents, biotechnology development, drug development, unmet medical needs, biopharmaceutical research
Industry3 codes
1Rare Pediatric & Congenital Disorder Therapies
CodeHLAIAIANPrimaryYes
2Specialty Injectable & Infusion Therapies (Cross-therapeutic)
CodeHLAIACAOPrimaryNo
3Immunology & Inflammation Pharmaceuticals
CodeHLAIAAADPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Therapeutic Biotechnology
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily focused on disease areas with high unmet needs. The company operates as a biotechnology research and development entity, creating novel therapeutic candidates for medical conditions lacking adequate treatment options.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • PAPZIMEOS received full FDA approval - first immunotherapy approved for recurrent respiratory papillomatosis
Product overview1 text field

Precigen operates as a biotechnology company with a focused therapeutic pipeline. The company's primary product is PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for recurrent respiratory papillomatosis. The pipeline platform showcases additional therapeutic candidates across various therapeutic areas and technology platforms.

Product and service1 record
1Therapeutic agents for diseases with high unmet needs
CategoryTherapeutic development
Description

Therapeutic agents under development targeting disease areas with high unmet medical needs. These are pharmaceutical candidates designed to treat conditions where existing treatment options are inadequate or unavailable.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Argenx
TypeDirect peer
Description

Belgian clinical-stage biotech focused on immunology/autoimmune therapeutics, headquartered near Ghent. Comparable as a Belgian immunology biotech with a specialty therapeutics pipeline targeting high-unmet-need indications.

2Galapagos NV
TypeDirect peer
Description

Belgian biotech developing specialty therapeutics in inflammation and immunology. Comparable due to Belgian operating base, immunology focus, and specialty pharmaceutical orientation.

3uniQure N.V.
TypeDirect peer
Description

Netherlands-based gene therapy company developing AAV-based therapeutics for rare diseases. Comparable due to European operating base, gene-delivery platform technology, and rare-disease therapeutic focus.

4Orchard Therapeutics
TypeDirect peer
Description

Gene therapy company developing ex vivo autologous therapies for rare diseases. Comparable due to genetic-medicine platform, rare-disease pipeline focus, and specialty biologics commercial model.

5Ultragenyx Pharmaceutical
TypeDirect peer
Description

Clinical-stage biotech developing novel therapies for rare and ultra-rare diseases, including biologics and gene therapies. Comparable due to rare-disease specialty focus and biologic modality.

6Adaptimmune Therapeutics
TypeEmerging player
Description

Cell therapy biotech developing engineered T-cell receptor therapies for solid tumors. Comparable as an emerging gene/cell-based therapeutic developer with a focus on difficult-to-treat indications.

7Precigen, Inc.
TypeBroad incumbent
Description

US-based parent company developing precision genetic medicines, including PAPZIMEOS. Comparable as the operating umbrella for ActoBio's commercial product and proprietary gene-delivery/manufacturing platforms.

8Sarepta Therapeutics
TypeBroad incumbent
Description

Established commercial-stage gene therapy company focused on rare neuromuscular diseases. Comparable as a broader incumbent in rare-disease genetic medicines with established specialty distribution.

9BioMarin Pharmaceutical
TypeBroad incumbent
Description

Large commercial-stage rare-disease specialty biotech with multiple approved biologics and enzyme replacement therapies. Comparable as a broad incumbent in rare-disease specialty therapeutics.

10Solid Biosciences
TypeEmerging player
Description

Clinical-stage genetic medicines company developing AAV-based therapies for rare diseases. Comparable as an emerging player in the same genetic-medicine platform category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ActoBio Therapeutics

Therapeutic Biotechnologyactobio.com

ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs.

What ActoBio Therapeutics does

ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs. It develops a new class of therapeutic agents called ActoBiotics, a targeted, microbe-based, specifically designed agents that locally provide potential disease-modifying therapeutics to treat a range of disorders, such as immune-related diseases. ActoBiotics is based on the safe food-grade bacterium, Lactococcus lactis, which is used in the making of cheeses and other foods. Lactococcus lactis is engineered to develop specific therapeutic agents for delivery directly to the relevant tissue, thus making therapeutic applications across many diseases. This holds safer and more efficacious treatments than injectable agents. The company has a strong research and development pipeline with stage candidate in Phase IIb, and an extensive portfolio of candidates ready for clinical development across a wide range of potential indications. ActoBio Therapeutics was founded on 2006 and is headquartered in Ghent. Belgium.

ActoBio Therapeutics firmographics

Firmographics
Name
ActoBio Therapeutics
Legal name
ActoBio Therapeutics, Inc.
Website
https://actobio.com/
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs.
Ownership category
akta.pro rank

ActoBio Therapeutics industry classification

Industry
Product category
Therapeutic Biotechnology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro primary industry
Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
akta.pro secondary industries
Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

  • Therapeutic agents
  • Biotechnology development
  • Drug development
  • Unmet medical needs
  • Biopharmaceutical research

Where ActoBio Therapeutics is headquartered

Location

Headquarters

HQ city
Ghent
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

ActoBio Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Distribution channels1 record

Marketing channels5 records

ActoBio Therapeutics product offering

Product offering

Core offering

ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily focused on disease areas with high unmet needs. The company operates as a biotechnology research and development entity, creating novel therapeutic candidates for medical conditions lacking adequate treatment options.

Product overview

Precigen operates as a biotechnology company with a focused therapeutic pipeline. The company's primary product is PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for recurrent respiratory papillomatosis. The pipeline platform showcases additional therapeutic candidates across various therapeutic areas and technology platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Therapeutic agents for diseases with high unmet needs Therapeutic agents under development targeting disease areas with high unmet medical needs. These are pharmaceutical candidates designed to treat conditions where existing treatment options are inadequate or unavailable.

Quantifiable outcome

  • PAPZIMEOS received full FDA approval - first immunotherapy approved for recurrent respiratory papillomatosis

Companies that use ActoBio Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

ActoBio Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

ActoBio Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves2 records

Expansion highlights1 record

ActoBio Therapeutics competitors and assessment

Company assessment

Direct peers

  • Argenx: Belgian clinical-stage biotech focused on immunology/autoimmune therapeutics, headquartered near Ghent. Comparable as a Belgian immunology biotech with a specialty therapeutics pipeline targeting high-unmet-need indications.
  • Galapagos NV: Belgian biotech developing specialty therapeutics in inflammation and immunology. Comparable due to Belgian operating base, immunology focus, and specialty pharmaceutical orientation.
  • uniQure N.V. Netherlands-based gene therapy company developing AAV-based therapeutics for rare diseases. Comparable due to European operating base, gene-delivery platform technology, and rare-disease therapeutic focus.
  • Orchard Therapeutics: Gene therapy company developing ex vivo autologous therapies for rare diseases. Comparable due to genetic-medicine platform, rare-disease pipeline focus, and specialty biologics commercial model.
  • Ultragenyx Pharmaceutical: Clinical-stage biotech developing novel therapies for rare and ultra-rare diseases, including biologics and gene therapies. Comparable due to rare-disease specialty focus and biologic modality.

Emerging players

  • Adaptimmune Therapeutics: Cell therapy biotech developing engineered T-cell receptor therapies for solid tumors. Comparable as an emerging gene/cell-based therapeutic developer with a focus on difficult-to-treat indications.
  • Solid Biosciences: Clinical-stage genetic medicines company developing AAV-based therapies for rare diseases. Comparable as an emerging player in the same genetic-medicine platform category.

Broad incumbents

  • Precigen, Inc. US-based parent company developing precision genetic medicines, including PAPZIMEOS. Comparable as the operating umbrella for ActoBio's commercial product and proprietary gene-delivery/manufacturing platforms.
  • Sarepta Therapeutics: Established commercial-stage gene therapy company focused on rare neuromuscular diseases. Comparable as a broader incumbent in rare-disease genetic medicines with established specialty distribution.
  • BioMarin Pharmaceutical: Large commercial-stage rare-disease specialty biotech with multiple approved biologics and enzyme replacement therapies. Comparable as a broad incumbent in rare-disease specialty therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

ActoBio Therapeutics social profiles

Digital presence

ActoBio Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ActoBio Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

ActoBio Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ActoBio Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ActoBio Therapeutics

What does ActoBio Therapeutics do?

ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily focused on disease areas with high unmet needs. The company operates as a biotechnology research and development entity, creating novel therapeutic candidates for medical conditions lacking adequate treatment options.

When was ActoBio Therapeutics founded?

ActoBio Therapeutics was founded in 2006. It employs 11 to 50 people.

Where is ActoBio Therapeutics based?

ActoBio Therapeutics is headquartered in Ghent, Belgium, in the Europe region.

Who are ActoBio Therapeutics's main competitors?

Direct peers on record are Argenx, Galapagos NV, uniQure N.V., Orchard Therapeutics and Ultragenyx Pharmaceutical. Emerging players are Adaptimmune Therapeutics and Solid Biosciences. Broad incumbents are Precigen, Inc., Sarepta Therapeutics and BioMarin Pharmaceutical.

Does ActoBio Therapeutics have an API?

No public API is recorded for ActoBio Therapeutics.

What industry is ActoBio Therapeutics in?

ActoBio Therapeutics's product category is Therapeutic Biotechnology. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325414 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of GlutenActoBio Therapeutics received Investigational New Drug (IND) permission from the U.S. FDA for AG017, an antigen-specific immunotherapy candidate designed to treat celiac disease. The company plans to enroll patients in a Phase Ib/IIa clinical study in the U.S. and Europe later in 2019 to evaluate the therapy's potential to reverse gluten sensitivity.PR NewswireActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 DiabetesActoBio Therapeutics announced that its investigational drug AG019 for type 1 diabetes will progress to the next stage of its Phase Ib/IIa clinical trial, following a favorable review by the independent Data and Safety Monitoring Board. The company will now enroll patients aged 12-17 years and test AG019 in combination with teplizumab (PRV-031) under a collaboration with Provention Bio. Results from the trial are expected in 2020 and will provide initial safety and efficacy data for AG019 in humans.PR NewswireIntrexon to Participate in 2019 BIO International ConventionIntrexon Corporation announced that it and its subsidiaries, ActoBio Therapeutics and Precigen, will participate in the 2019 BIO International Convention in Philadelphia. Executives from these entities are scheduled to present on topics ranging from microbe-based therapeutics to immuno-oncology during the event held June 3-6.PR NewswireIntrexon Announces Presentations at Upcoming Investor ConferencesIntrexon Corporation announced that the company and its subsidiaries will present at upcoming investor conferences in San Francisco in January 2019, including the Biotech Showcase and the 37th Annual J.P. Morgan Healthcare Conference. Various executives from Intrexon and its subsidiaries ActoBio Therapeutics, Xogenex, and Precigen will make presentations at these events, with live webcasts available on the company's investor relations website. The announcement includes RSVP requirements for in-person attendance at an investor event featuring Precigen's preclinical and clinical portfolio on January 7, 2019.PR NewswireIntrexon Announces Third Quarter 2018 Financial ResultsIntrexon Corporation reported Q3 2018 financial results with GAAP revenues of $32.4 million, a 30% decrease year-over-year, and a net loss attributable to the company of $57.3 million including $38.7 million in non-cash charges, with Adjusted EBITDA of negative $28.9 million. The company highlighted commercial achievements across its portfolio including Okanagan Specialty Fruits' Arctic Apple harvest yielding ten times last year's production, EnviroFlight's phase one BSFL facility opening, and several clinical and technical milestones from subsidiaries including Precigen, Oxitec, ActoBio Therapeutics, and Fibrocell Science. CEO Randal J. Kirk stated the company is transitioning from science and technology to products and product candidates, with a focus on commercialization of transformative offerings.PR NewswireActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 DiabetesActoBio Therapeutics, a subsidiary of Intrexon Corporation, and Intrexon T1D Partners announced the first patient has been dosed in a Phase Ib/IIa clinical trial for AG019, a microbe-based therapeutic designed to induce immune tolerance in early onset type 1 diabetes. The trial will test AG019 alone in Phase Ib and in combination with teplizumab in Phase IIa across clinical sites in the US and Belgium, with results expected in early 2020. Pre-clinical studies showed that AG019 combined with anti-CD3 antibody successfully reverted normal blood sugar levels in 60% of diabetic mice and reversed the disease in 89% of early-stage treated mice.PR NewswireActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 DiabetesThe U.S. Food and Drug Administration has granted Investigational New Drug (IND) allowance to ActoBio Therapeutics and Intrexon T1D Partners LLC to initiate a Phase Ib/IIa clinical trial for AG019, an oral capsule therapy for early onset type 1 diabetes. AG019 uses engineered L. lactis bacteria to deliver human proinsulin and IL-10, aiming to re-establish immunological tolerance by producing regulatory T-cells. Preclinical studies in animal models demonstrated diabetes remission rates of approximately 60% with AG019 alone and up to 89% when combined with anti-CD3 monoclonal antibody treatment.PR NewswireIntrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation, announced that its CEO will present at the Biotech Showcase 2018 Conference in San Francisco on January 8, highlighting their proprietary ActoBiotics® drug delivery platform for oral and topical administration of biologicals. The platform targets unmet medical needs across oral, gastrointestinal, and autoimmune/allergic disorders, with the most advanced therapeutic candidate currently in Phase 2b clinical trials and an extensive portfolio of candidates in the pipeline. The company positioned this as a milestone in advancing their therapeutic development across multiple markets with strong growth dynamics.